Page 3 - Activating Construct News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium

19.12.2023 - SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) - Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced abstract acceptance and an upcoming rapid oral . Seite 1

United statesSan franciscoHimisha beltranDrug administrationMd dana farber cancer instituteHarpoon therapeutics incHarpoon therapeutics abstractRapid oral presentationClinical oncology genitourinary cancers symposiumAmerican societyActivating constructT cell engagerNeuroendocrine prostate cancerNeuroendocrine neoplasmsRapid oral abstract sessionProstate cancer

Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)

Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesLuke walkerSumit madanBanner md anderson cancer centerUt md anderson cancer centerHarpoon therapeutics incAmerican society of hematologyExchange commissionAmerican societyAnnual meetingOverall response rateVery good partial responseCancer centerAssociate professorChief medical officer

Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition

Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoSumit madanHarpoon therapeutics incAmerican society of hematologyBanner md anderson cancer centerExchange commissionTherapeutics abstractAmerican societyAnnual meetingCompleted dose escalation portionTargetingb cell maturation antigenRefractory multiple myelomaProspective therapeutics trialsRefractory myelomaManchester grand hyatt san diego

Harpoon Therapeutics Announces Up to $150 Million Private Placement

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 Harpoon Therapeutics, Inc. , a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it has entered into a.

United statesCanaccord genuityGlobenewswire incHc wainwright coHarpoon therapeutics incExchange commissionLeaf venture partnersCormorant asset managementBridge groupPoint capitalSecurities actActivating constructHarpoon therapeuticsPrivate securities litigation reform act

Harpoon Therapeutics Announces Updated Interim Tolerability

Confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, including three confirmed, complete.

Noura choudhuryLuke walkerMemorial sloan kettering cancer centerExchange commissionEuropean society of medical oncology congressHarpoon therapeutics incDrug administrationEuropean societyMedical oncology congressActivating constructPrincipal investigatorChief medical officerOrphan drug designationHarpoon therapeuticsPrivate securities litigation reform actHarpoon therapeutic